RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2023 -- Pappas Capital, a leading investor in next-generation life science and technology companies, announced today that Nick Pappas (no relation) has joined the firm as...
Veralox is a clinical stage company developing first-in-class small molecule therapeutics that treat the underlying pathologies of immuno-inflammatory diseases heparin-induced thrombocytopenia (HIT) and type 1 diabetes (T1D), as well as several programs in the discovery phase.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.